Titan Biotech (Small Cap - Next Multibagger) Share Target 2024, 2025 To 2039
|
Titan Biotech Limited |
|||
|
Price: ₹720.50 | ||
| 52 Week Low: ₹400.10 52 Week High: ₹1,017.85 |
|||
| Market Capital: 450.12 Crore (Smallcap) | |||
| -> | |||
Show Table of Contents
Table of Contents
- 1: Approach 1: Technical Analysis Paired With Price Action
- 1.1: Titan Biotech Share Price Target For 2024
- 1.1.1: Titan Biotech Share Price Target Table For 2024
- 1.1.2: Short-Term Technical Outlook
- 1.2: Titan Biotech Share Price Target For 2025
- 1.2.1: Titan Biotech Share Price Target Table For 2025
- 1.2.2: Long-Term Technical Outlook
- 2: Approach 2: Machine Learning By Studying Historical Prices
- 2.1: Titan Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
- 3: Titan Biotech Financial Performance
- 3.0.1: Is Titan Biotech A Good Buy For Long Term?
To predict the Titan Biotech's future market prices, we harnessed 2 dynamic approaches:
Approach 1: Technical Analysis Paired With Price Action
Approach 2: Machine Learning By Studying Historical Prices
Approach 1: Technical Analysis Paired With Price Action
Titan Biotech Share Price Target For 2024
The line chart displays the monthly closing prices of Titan Biotech with a black line. The green line shows three potential target prices for 2024, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Titan Biotech shares in 2024, see the table below.
Titan Biotech Share Price Target Table For 2024
| Level | Value | Analysis |
|---|---|---|
| 2024 Target 3 | 767.9 (+6.57%) | Price Action: 22 Nov 2024 High |
| 2024 Target 2 | 760.05 (+5.48%) | Price Action: 16 Dec 2024 Low |
| 2024 Target 1 | 750.0 (+4.09%) | Price Action: 28 Nov 2024 Low |
| Current Price | 720.50 | Titan Biotech's share price as of 23 Dec 2024 |
| Stop Loss 1 | 700.0 (-2.85%) | Price Action: Oct 2024 Low |
| Stop Loss 2 | 683.25 (-5.18%) | Technical Indicator: MA150 |
| Stop Loss 3 | 670.95 (-6.88%) | Price Action: Chart |
Short-Term Technical Outlook
Current Technical Position: Titan Biotech is displaying bearish momentum trading below key moving averages.
Key Technical Level: The 25-day moving average at ₹787.2 serves as the nearest technical reference point.
Historical Returns: 3-month: +6.66% | 6-month: +24.17% | 1-year: +84.87%
Titan Biotech Share Price Target For 2025
The line chart displays the monthly closing prices of Titan Biotech with a black line. The green line shows three potential target prices for 2025, while the red line indicates three potential Stop Loss levels.
For detailed target and stop loss values for Titan Biotech shares in 2025, see the table below.
Titan Biotech Share Price Target Table For 2025
| Level | Value | Analysis |
|---|---|---|
| 2025 Target 3 | 1169.82 (+62.36%) | Fibonacci Extension Level 123.60% |
| 2025 Target 2 | 1149.83 (+59.58%) | Price Action: Chart |
| 2025 Target 1 | 1138.45 (+58%) | Fibonacci Extension Level 64.90% |
| Current Price | 720.50 | Titan Biotech's share price as of 23 Dec 2024 |
| Stop Loss 1 | 616.11 (-14.49%) | Price Action: Feb 2024 High |
| Stop Loss 2 | 609.95 (-15.35%) | Price Action: Chart |
| Stop Loss 3 | 598.97 (-16.87%) | Price Action: Chart |
Long-Term Technical Outlook
52-Week Range Analysis: Titan Biotech is currently trading at 51.9% of its 52-week range (₹400.1 - ₹1017.85).
Long-Term Trend Analysis: The stock is maintaining a bullish long-term trend, trading above both 150-day and 250-day moving averages.
Long-Term Performance: 1-year: +84.87% | 3-year: +158.31% | 5-year: +1,801.03%
Stay ahead of the market! Get instant alerts on crucial market breakouts. Don't miss out on key opportunities!
Your phone number will be HIDDEN to other users.
Approach 2: Machine Learning By Studying Historical Prices
Titan Biotech Share Price Target Chart and Table From 2024, 2025, 2026 to 2039
| Year | Target 1 | Target 1 YoY Chg % | Target 2 |
|---|---|---|---|
| Current Price | ₹720.50 | ||
| 2024 | ₹926.63 | +28.6% | ₹940.53 |
| 2025 | ₹1,403.66 | +51.48% | ₹1,424.71 |
| 2026 | ₹1,799.32 | +28.18% | ₹1,826.31 |
| 2027 | ₹2,360.22 | +31.17% | ₹2,454.01 |
| 2028 | ₹3,088.69 | +30.86% | ₹3,135.02 |
| 2029 | ₹3,448.59 | +11.65% | ₹3,500.32 |
| 2030 | ₹3,877.39 | +12.43% | ₹3,935.55 |
| 2031 | ₹4,143.93 | +6.87% | ₹4,424.38 |
| 2032 | ₹4,799.91 | +15.82% | ₹5,081.97 |
| 2033 | ₹5,734.42 | +19.46% | ₹5,820.44 |
| 2034 | ₹5,970.55 | +4.11% | ₹6,060.11 |
| 2035 | ₹6,351.12 | +6.37% | ₹6,446.39 |
| 2036 | ₹6,488.54 | +2.16% | ₹7,104.95 |
| 2037 | ₹7,239.59 | +11.57% | ₹7,779.28 |
| 2038 | ₹8,380.14 | +15.75% | ₹8,505.84 |
| 2039 | ₹8,203.28 | -2.11% | ₹8,365.12 |
Note: Target 1 and Target 2 represent price levels that the stock is most likely to achieve during the respective year, based on machine learning algorithms analyzing historical price patterns and market behavior. These predictions are generated through comprehensive analysis of the stock's historical data using advanced ML models.
Titan Biotech Financial Performance
| Metric | Value | Description |
|---|---|---|
| Market Capital | 450.12 Crore | Market valuation of Titan Biotech's shares. |
| Revenue (TTM) | 143.99 Crore | Total revenue generated by Titan Biotech over the past twelve months. |
| Net Income (TTM) | +24.84 Crore | Net Profit or Loss after all the expenses over the past twelve months. |
| Operating Margin | +20.04% | Income from operations as a percentage of revenue, before taxes and interest. |
| Profit Margin | +51.47% | Net income as a percentage of revenue, after all expenses. |
| Revenue Growth (Quarterly) |
+5.87% | Change in revenue compared to the previous quarter. |
| Debt-to-Equity (D/E) Ratio |
0.07 | Company's total debt divided by total shareholder equity. |
| Total Debt | 8.56 Crore | Sum of Titan Biotech's current & long-term financial obligations. |
Is Titan Biotech A Good Buy For Long Term?
Titan Biotech's strong financial performance, with a 51.47% profit margin and consistent revenue growth of 5.87% in the last quarter, indicates its potential as a long-term investment. The company's impressive past returns, including a 131.78% return over the last year and a 264.59% return over the last 3 years, further support its growth trajectory. However, it's important to note the company's debt of 8.56 Crore, which may require further analysis to assess its impact on future profitability. Overall, Titan Biotech appears to be a promising investment opportunity for long-term investors seeking growth potential.
Disclaimer: The information provided on this page is for educational purposes only and should not be considered as financial advice. Historical performance data and technical analysis cannot guarantee future results. Stock investments are subject to market risks. Please consult with a qualified financial advisor before making any investment decisions.
All stock data shown is sourced from publicly available information and while we strive for accuracy, we cannot guarantee the absolute accuracy of all figures. Users should verify critical information from official sources before making investment decisions.
